Spotlight on drug pricing could be catalyst for change in US biosimilar landscape
While biosimilar makers have long established themselves in Europe, only a few copycat versions of biologics have launched in the nascent US market, which is beginning to show signs of maturing, but is complicated by a reimbursement landscape fractured by multiple players. The spotlight on drug pricing, however, may at long last provide the catalyst for change.
Biosimilars were approved in the United States amidst much fanfare in 2015, years after their introduction in Europe, thanks partly to the tactics employed by Big Pharma to evergreen the patent protection of their prized blockbuster biologics in the world’s biggest market for drugs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
